Apolipoprotein E ε4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: A 15-year disease history model based on a 4-year longitudinal study

Folia Biologica

Volumn 56, Issue 6, 2010, Pages 242-251

  Horáková, Dana ^a   Kyr M ^b,d   Havrdova E ^a   Dolezal O ^a   Lelkova P ^a   Pospisilova L ^a   Bergsland, N ^c   Dwyer, M G ^c   Cox, J L ^c   Hussein, S ^c   Seidl, Z ^a   Vaneckova M ^a   Krasensky J ^a   Zivadinov, R ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

APOE; Brain atrophy; Gray matter; Mixed effect model; MRI; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN E4; GENOMIC DNA;

ADULT; ARTICLE; BRAIN ATROPHY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENOTYPE; GRAY MATTER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; STATISTICAL MODEL; TIME; WHITE MATTER;

BOVINE PARVOVIRUS;

EID: 78651291539     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Barger, S. W., Harmon, A. D. (1997) Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881.
2. Bertram, L., Tanzi, R. E. (2008) Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci. 9, 768-778.
3. Bu, G. (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333-344.
4. Burt, T. D., Agan, B. K., Marconi, V. C., He, W., Kulkarni, H., Mold, J. E., Cavrois, M., Huang, Y., Mahley, R. W., Dolan, M. J., McCune, J.M., Ahuja, S. K. (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE ε4/ε4 genotype accelerates HIV disease progression. Proc. Natl. Acad. Sci. USA 105, 8718-8723.
5. Burwick, R. M., Ramsay, P. P., Haines, J. L., Hauser, S. L., Oksenberg, J. R., Pericak-Vance, M. A., Schmidt, S., Compston, A., Sawcer, S., Cittadella, R., Savettieri, G., Quattrone, A., Polman, C. H., Uitdehaag, B. M., Zwemmer, J. N., Hawkins, C. P., Ollier, W. E., Weatherby, S., Enzinger, C., Fazekas, F., Schmidt, H., Schmidt, R., Hillert, J., Masterman, T., Hogh, P., Niino, M., Kikuchi, S., Maciel, P., Santos, M., Rio, M. E., Kwiecinski, H., Zakrzewska-Pniewska, B., Evangelou, N., Palace, J., Barcellos, L. F. (2006) APOE ε variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 66, 1373-1383.
6. Chapman, J., Vinokurov, S., Achiron, A., Karussis, D. M., Mitosek-Szewczyk, K., Birnbaum, M., Michaelson, D. M., Korczyn, A. D. (2001) APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 56, 312-316.
7. Dalton, C. M., Chard, D. T., Davies, G. R., Miszkiel, K. A., Altmann, D. R., Fernando, K., Plant, G. T., Thompson, A. J., Miller, D. H. (2004) Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127, 1101-1107.
8. De Stefano, N., Bartolozzi, M. L., Nacmias, B., Zipoli, V., Mortilla, M., Guidi, L., Siracusa, G., Sorbi, S., Federico, A., Amato, M. P. (2004) Influence of apolipoprotein E ε4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch. Neurol. 61, 536-540.
9. Enzinger, C., Ropele, S., Strasser-Fuchs, S., Kapeller, P., Schmidt, H., Poltrum, B., Schmidt, R., Hartung, H. P., Fazekas, F. (2003) Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E ε4 allele. Arch. Neurol. 60, 65-70.
10. Enzinger, C., Ropele, S., Smith, S., Strasser-Fuchs, S., Poltrum, B., Schmidt, H., Matthews, P. M., Fazekas, F. (2004) Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-ε 4. Ann. Neurol. 55, 563-569.
11. Fazekas, F., Strasser-Fuchs, S., Schmidt, H., Enzinger, C., Ropele, S., Lechner, A., Flooh, E., Schmidt, R., Hartung, H. P. (2000) Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 69, 25-28.
12. Fazekas, F., Strasser-Fuchs, S., Kollegger, H., Berger, T., Kristoferitsch, W., Schmidt, H., Enzinger, C., Schiefermeier, M., Schwarz, C., Kornek, B., Reindl, M., Huber, K., Grass, R., Wimmer, G., Vass, K., Pfeiffer, K. H., Hartung, H. P., Schmidt, R. (2001) Apolipoprotein E ε 4 is associated with rapid progression of multiple sclerosis. Neurology 57, 853-857.
13. Fisher, E., Lee, J. C., Nakamura, K., Rudick, R. A. (2008) Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255-265.
14. Fisniku, L. K., Chard, D. T., Jackson, J. S., Anderson, V. M., Altmann, D. R., Miszkiel, K. A., Thompson, A. J., Miller, D. H. (2008) Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol. 64, 247-254.
15. Gerdes, L.U., Klausen, I.C., Sihm, I. and Faergeman, O. (1992) Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet. Epidemiol. 9, 155-167.
16. Haines, J. L., Bradford, Y., Garcia, M. E., Reed, A. D., Neumeister, E., Pericak-Vance, M. A., Rimmler, J. B., Menold, M. M., Martin, E. R., Oksenberg, J. R., Barcellos, L. F., Lincoln, R., Hauser, S. L. (2002) Multiple susceptibility loci for multiple sclerosis. Hum. Mol. Genet. 11, 2251-2256.
17. Havrdova, E., Zivadinov, R., Krasensky, J., Dwyer, M. G., Novakova, I., Dolezal, O., Ticha, V., Dusek, L., Houzvickova, E., Cox, J. L., Bergsland, N., Hussein, S., Svobodnik, A., Seidl, Z., Vaneckova, M., Horakova, D. (2009) Randomized study of interferon β-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult. Scler. 15, 965-976.
18. Hixson, J. E., Vernier, D. T. (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J. Lipid. Res. 31, 545-548.
19. Hogh, P., Oturai, A., Schreiber, K., Blinkenberg, M., Jorgensen, O. S., Ryder, L., Paulson, O. B., Sorensen, P. S., Knudsen, G. M. (2000) Apoliprotein E and multiple sclerosis: impact of the ε-4 allele on susceptibility, clinical type and progression rate. Mult. Scler. 6, 226-230.
20. Horakova, D., Cox, J. L., Havrdova, E., Hussein, S., Dolezal, O., Cookfair, D., Dwyer, M. G., Seidl, Z., Bergsland, N., Vaneckova, M., Zivadinov, R. (2008) Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J. Neurol. Neurosurg. Psychiatr. 79, 407-414.
21. Horakova, D., Dwyer, M. G., Havrdova, E., Cox, J. L., Dolezal, O., Bergsland, N., Rimes, B., Seidl, Z., Vaneckova, M., Zivadinov, R. (2009) Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J. Neurol. Sci. 282, 112-119.
22. Koutsis, G., Panas, M., Giogkaraki, E., Potagas, C., Karadima, G., Sfagos, C., Vassilopoulos, D. (2007) APOE ε4 is associated with impaired verbal learning in patients with MS. Neurology 68, 546-549.
23. Kurtzke, J. F. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452.
24. Laskowitz, D. T., Horsburgh, K., Roses, A. D. (1998) Apolipoprotein E and the CNS response to injury. J. Cereb. Blood Flow Metab. 18, 465-471.
25. Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P .M., Warner, D. S., Laskowitz, D. T. (2003) APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 278, 48529-48533.
26. Mahley, R.W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science, 240, 622-630.
27. Martinez, M., Brice, A., Vaughan, J. R., Zimprich, A., Breteler, M. M., Meco, G., Filla, A., Farrer, M. J., Betard, C., Singleton, A., Hardy, J., De Michele, G., Bonifati, V., Oostra, B. A., Gasser, T., Wood, N. W., Durr, A. (2005) Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 136B, 72-74.
28. Masterman, T., Zhang, Z., Hellgren, D., Salter, H., Anvret, M., Lilius, L., Lannfelt, L., Hillert, J. (2002) APOE genotypes and disease severity in multiple sclerosis. Mult. Scler. 8, 98-103.
29. Miller, S. A., Dykes, D. D., Polesky, H. F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
30. Nobre, J. S., da Motta Singer, J. (2007) Residual analysis for linear mixed models. Biomed. J. 49, 863-875.
31. Pinholt, M., Frederiksen, J. L., Andersen, P. S., Christiansen, M. (2005) Apo E in multiple sclerosis and optic neuritis: the apo E-ε4 allele is associated with progression of multiple sclerosis. Mult. Scler. 11, 511-515.
32. Pinholt, M., Frederiksen, J. L., Christiansen, M. (2006) The association between apolipoprotein E and multiple sclerosis. Eur. J. Neurol. 13, 573-580.
33. Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., Tourtellotte, W. W. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227-231.
34. Savettieri, G., Andreoli, V., Bonavita, S., Cittadella, R., Caltagirone, C., Fazio, M. C., Girlanda, P., Le Pira, F., Liguori, M., Logroscino, G., Lugaresi, A., Nocentini, U., Reggio, A., Salemi, G., Serra, P., Tedeschi, G., Toma, L., Trojano, M., Valentino, P., Quattrone, A. (2003) Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J. Neurol. 250, 1094-1098.
35. Savettieri, G., Messina, D., Andreoli, V., Bonavita, S., Caltagirone, C., Cittadella, R., Farina, D., Fazio, M.C., Girlanda, P., Le Pira, F., Liguori, M., Lugaresi, A., Nocentini, U., Reggio, A., Salemi, G., Tedeschi, G., Trojano, M., Valentino, P. and Quattrone, A. (2004) Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol. 251, 1208-1214.
36. Schmidt, S., Barcellos, L. F., DeSombre, K., Rimmler, J. B., Lincoln, R. R., Bucher, P., Saunders, A. M., Lai, E., Martin, E. R., Vance, J. M., Oksenberg, J. R., Hauser, S. L., Pericak-Vance, M. A., Haines, J. L. (2002) Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am. J. Hum. Genet. 70, 708-717.
37. Schreiber, K., Otura, A. B., Ryder, L. P., Madsen, H. O., Jorgensen, O. S., Svejgaard, A., Sorensen, P. S. (2002) Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult. Scler. 8, 295-298.
38. Shi, J., Zhao, C. B., Vollmer, T. L., Tyry, T. M., Kuniyoshi, S. M. (2008) APOE ε4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology 70, 185-190.
39. Siest, G., Pillot, T., Regis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., Visvikis, S. (1995) Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin. Chem. 41, 1068-1086.
40. Singer, J., Willett, J. (2003) Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford University Press, New York.
41. Smith, S. M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P. M., Federico, A., De Stefano, N. (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 17, 479-489.
42. Valsasina, P., Benedetti, B., Rovaris, M., Sormani, M. P., Comi, G., Filippi, M. (2005) Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 65, 1126-1128.
43. Verbeke, G., Molenberghs, G. (2000) Linear Mixed Models for Longitudinal Data. Springer-Verlag, New York-Berlin-Heidelberg.
44. Weatherby, S. J., Mann, C. L., Davies, M. B., Carthy, D., Fryer, A. A., Boggild, M. D., Young, C., Strange, R. C., Ollier, W., Hawkins, C. P. (2000) Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult. Scler. 6, 32-36.
45. Zakrzewska-Pniewska, B., Styczynska, M., Podlecka, A., Samocka, R., Peplonska, B., Barcikowska, M., Kwiecinski, H. (2004) Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult. Scler. 10, 266-271.
46. Zivadinov, R., Grop, A., Sharma, J., Bratina, A., Tjoa, C. W., Dwyer, M., Zorzon, M. (2005) Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis. J. Neuroimaging 15, 27-36.
47. Zwemmer, J. N., van Veen, T., van Winsen, L., van Kamp, G. J., Barkhof, F., Polman, C. H., Uitdehaag, B. M. (2004) No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult. Scler. 10, 272-277.